hero image

Biogen Statement about Director and Chair of the Compensation and Management Development Committee Robert W. Pangia

June 2, 2021 Company Statements

Robert W. Pangia, who has served as a Biogen director since 1997, will retire from the company’s Board this year, effective at the annual meeting of stockholders. Biogen and the Board of Directors would like to thank Bob for his decades-long service and invaluable support.
 
In Bob’s nearly quarter-century tenure on the Biogen Board, he has supported the development of the company’s best-in-class governance principles, which have been critical to our success and to obtaining the trust and confidence of all our stakeholders. The Board has drawn upon Bob’s extensive financial and executive leadership experience during his time as Chair of the Compensation and Management Development Committee, leveraging his expertise to ensure and maintain the integrity of the company as we navigated life in the public domain.

With a background in healthcare investing and an entrepreneurial spirit, Bob has been attuned to the intricacies of our industry and well aligned with and supportive of our long-held mission of becoming a neuroscience pioneer that today discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. 

Bob has been an indispensable contributor to the Board and supported the company’s development through his wise counsel and active engagement. We are deeply grateful for his service and wish him the best for the future.
 

thumb
July 29, 2021
Late-Breaking AAIC Presentation Explores Potential Clinical Effects of LECANEMAB (BAN240)

Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab Following  18 Months of Treatment in the Open-Label Extension of the Phase 2 Proof of Concept Study at  2021 Alzheimer’s Association International Conference (AAIC)   Eisai Co., Ltd.

thumb
July 29, 2021
Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer’s Disease at AAIC 2021

ICARE AD-US is an observational real-world phase 4 study designed to evaluate the safety and effectiveness of ADUHELM in clinical practice ICARE AD-US is one of three programs to generate post-approval data on ADUHELM, including the re-dosing Phase 3b EMBARK study and the planned confirmatory Phase